Project description
Novel testing methods for metabolism-disrupting chemicals
Metabolism-disrupting chemicals (MDCs) are natural and anthropogenic chemicals that disrupt the metabolism and ultimately result in obesity and diabetes. The EU-funded GOLIATH project aims to develop an integrated approach for testing and assessing MDCs. Researchers will focus on the main cellular targets of metabolic disruption and develop predictive models as well as toxicity screening assays. Combined with omics data, these tools will help decipher the endocrine mode of action and the adverse effects of MDCs on human health. The GOLIATH test methods have the potential to be exploited for regulatory use, leading to much anticipated guidelines.
Objective
GOLIATH addresses the work programme topic ‘SC1-BHC-27-2018: New testing and screening methods to identify endocrine disrupting chemicals (EDCs)’ by focussing on one of the most urgent regulatory needs, namely the lack of methods for testing EDCs that disrupt metabolism – chemicals collectively referred to as ‘metabolism disrupting chemicals’ (MDCs). MDCs are natural and anthropogenic chemicals that have the ability to promote metabolic changes that can ultimately result in obesity, diabetes and/or fatty liver in humans. GOLIATH will generate the world’s first integrated approach to testing and assessment (IATA) specifically tailored to MDCs. With a focus on the main cellular targets of metabolic disruption – hepatocytes, pancreatic endocrine cells, myocytes and adipocytes - GOLIATH will develop new methods and optimise existing methods that span the entire adverse outcome pathway (AOP) spectrum, using in silico predictive modelling and high throughput screening, (pre-)validated ready-to-use in vitro assays and optimised in vivo toxicity testing guidelines. GOLIATH will provide key information on the endocrine mode of action by which MDCs disrupt metabolic pathways and induce adverse effects on human health by incorporating multi-omics technologies, and translating results from in vitro and in vivo assays to adverse metabolic health outcomes in humans at real life exposures. Given the importance of international acceptance of the developed test methods for regulatory use, GOLIATH will link with ongoing initiatives of the OECD for test method (pre-)validation, IATA and AOP development. With a consortium comprised of world-leading experts in endocrinology, molecular biology, toxicology, epidemiology, test method development, validation and chemical regulation, GOLIATH will be pivotal in the development of an internationally harmonised strategy for testing MDCs, and help to reduce the worldwide rise in metabolic disorders that have reached ‘Goliathan’ proportions.
Fields of science
Keywords
Programme(s)
Topic(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
3584 CS Utrecht
Netherlands